An observational study in Prostate Cancer, sponsored by Xuanwu Hospital, Beijing. Status unknown. Open to male participants aged 30 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-30.
Sponsored by Xuanwu Hospital, Beijing · Observational
Immunotherapy is currently revolutionizing the field in oncology. However, prostate cancer is poorly responsive to immune checkpoint inhibition. The combination of immunotherapy and radiotherapy is an emerging clinical treatment aradigm. X-ray radiation treatment can activate both the adaptive and innate immune systems through directly killing tumor cells, causing mutations in tumor-derived peptides, and causing localized inflammation that increases immune cell trafficking to tumors. Recently, preclinical study reported that immune checkpoint inhibition combined with radiotherapy treats CPRC with significant increases in median survival compared to drug alone.
Permanent brachytherapy is one of those standard treatments for localized prostate cancer patients.
Biopsy confirms prostate cancer. Blood and urine of localized prostate cancer patients will be collected before and at different time points after permanent brachytherapy (1, 3, 6, and 12 months)
6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.
This study's planned enrollment of 20 is below the median of 200 across 1,181 observational studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Xuanwu Hospital, Beijing is the lead sponsor of 346 studies on the registry; 217 are open to participants now.
Counted across the registry records on this site, refreshed daily.
localized prostate cancer patients
Localized Prostate Cancer, ≤cT3
No chemotherapy or Hormonal therapy before Permanent Brachytherapy
Exclusion Criteria:
Poor anatomy which in the opinion of the radiation oncologist could lead to a suboptimal implant (e.g.,large or poorly healed transurethral resection of the prostate (TURP) defect, large median lobe, large gland size).
Pathologically positive lymph nodes
Significant obstructive uropathy
Distant metastases
Use steroids regularly
The diagnosis was accompanied by immune-related diseases
Allergic constitution
Abnormal white blood cell and lymphocyte counts
Ever underwent other treatments for prostate cancer, such as chemotherapy or Hormonal therapy
Accompanied by other malignancies
Splenectomy
HIV positive
Receive an anti-infective vaccine for the last 6 months
Briefly, the patient had a general anesthesia and PPB was performed by using the "real-time" intraoperative planning method guided by TRUS. The radioactive seeds were inserted transperineally according to a modified peripherally loaded Seattle technique 17. I-125 was used for all implants with a mean seed activity of 0.45 mCi per seed. All procedures were completed by a single surgeon.
the level of PD-L1-expressing regulatory T cells in blood and urine
the level of PD-L1-expressing regulatory T cells in blood and urine
Time frame: 2 year
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xuanwu Hospital, Beijing